ER-Phagosome pathway
gene
reagent
sample publication
sample review
B2M
beta-2-microglobulin
total:5
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. 2008 to the paper
Dako anti-B2m was used to perform immunohistochemistry in order to study the presence of specific populations of tumor infiltrating lymphocytes in diagnostic primary melanoma biopsies are associated with outcome in clinically stage II melanoma patients. more
calreticulin
total:39
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. 2010 to the paper
Stressgen anti-calreticulin antibody was used in western blot and immunocytochemistry to study the formation requirement of efficient hepatitis C virus particle. more
ERp57
protein disulfide isomerase family A member 3
total:4
Endoplasmic reticulum chaperones stabilize nicotinic receptor subunits and regulate receptor assembly. 2007 to the paper
Stressgen anti-ERp57 Ab (1:2000 dilution) was used western blot to study the role of endoplasmic reticulum chaperones on nicotinic receptor subunits and assembly more
gankyrin
proteasome 26S subunit, non-ATPase 10
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA B
major histocompatibility complex, class I, B
total:1
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. 2005 to the paper
PharMingen anti-HLA-B antibody was used in flow cytometry immunophenotyping to study the function of fibromodulin which serves as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) to enable the expansion of specific CD8+ autologous T lymphocytes
HLA E
major histocompatibility complex, class I, E
total:12
ESCRT-III governs the Aurora B-mediated abscission checkpoint through CHMP4C. 2012 to the paper
Serotec FITC-conjugated anti-MHC-I was used to perform flow cytometry in order to show that cell abscission mediated by Aurora B was regulated by ESCRT-III. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-A
major histocompatibility complex, class I, A
total:8
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. 2008 to the paper
Santa Cruz Biotechnology anti-HLA-A(A-18) antibody was used to perform immunohistochemistry in order to study tumor and tumor-stromal cell interactions. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-C
major histocompatibility complex, class I, C
total:7
Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. 2009 to the paper
Invitrogen Purified goat IgG was used as the isotypic controls in order to identify the MHC I molecule (HLA-C) as an attachment factor in facilitating HCoV-HKU1 spike (S) mediated infection. more
HLA-F
major histocompatibility complex, class I, F
total:1
Progressive myopathy and defects in the maintenance of myotendinous junctions in mice that lack talin 1 in skeletal muscle. 2008 to the paper
Sigma mouse monoclonal MHCf antibody was used in immunohistochemistry in order to study the role of talin 1 in the development and function of skeletal muscle
p44S10
proteasome 26S subunit, non-ATPase 6
PA200
proteasome activator subunit 4
total:1
Transformation of the proteasome with age-related macular degeneration. 2007 to the paper
Affinity Bioreagents proteasomal regulator PA200 antibody was used in western blot in order to investigate how proteasome changes with the disease of age-related macular degeneration (AMD).
PSMA1
proteasome 20S subunit alpha 1
total:9
Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. 2008 to the paper
Abcam C2 proteasome antibody was used in western blot in order to demonstrate that increased AA and insulin availability causes changes in anabolic signaling and amounts of enzymes of the ubiquitin-proteasome pathway more
PSMA3
proteasome 20S subunit alpha 3
total:3
Two histone marks establish the inner centromere and chromosome bi-orientation. 2010 to the paper
Santa Cruz Biotechnology anti-Psc3 antibody was used to carry out ChIP assays in order to investigate the mechanism for how inner centromere is established and how the CPC is targeted to this site. more
PSMA4
proteasome 20S subunit alpha 4
total:3
Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. 2010 to the paper
Affinity-Biomol International mouse monoclonal anti-human 20S proteasome subunit alpha4 was used for immunohistochemistry to investigate the effect of immunoproteasome on the Multiple Sclerosis pathogenesis. more
PSMA7
proteasome 20S subunit alpha 7
total:4
Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD. 2009 to the paper
Enzo Life Sciences anti-alpha7 antibody was used in western blot in order to identify a novel complex of erasin-ubiquilin-p97/VCP and its function in ERAD. more
PSMA8
proteasome 20S subunit alpha 8
PSMB1
proteasome 20S subunit beta 1
total:2
Transformation of the proteasome with age-related macular degeneration. 2007 to the paper
Affinity Bioreagents proteasomal subunit beta1 antibody was used in western blot in order to investigate how proteasome changes with the disease of age-related macular degeneration (AMD). more
PSMB10
proteasome 20S subunit beta 10
PSMB11
proteasome subunit beta 11
PSMB4
proteasome 20S subunit beta 4
PSMB5
proteasome 20S subunit beta 5
total:1
Transformation of the proteasome with age-related macular degeneration. 2007 to the paper
Affinity Bioreagents proteasomal subunit beta5 antibody was used in western blot in order to investigate how proteasome changes with the disease of age-related macular degeneration (AMD).
PSMB6
proteasome 20S subunit beta 6
PSMB7
proteasome 20S subunit beta 7
PSMB8
proteasome 20S subunit beta 8
total:3
Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. 2010 to the paper
Affinity-Biomol International anti-LMP7 antibody was used for immunohistochemistry to study the effect of immunoproteasome on the Multiple Sclerosis. more
PSMB9
proteasome 20S subunit beta 9
total:2
Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. 2010 to the paper
Affinity-Biomol International anti-LMP2 antibody was used to perform immunohistochemistry to study the role of immunoproteasome in the Multiple Sclerosis pathogenesis. more
PSMC1
proteasome 26S subunit, ATPase 1
PSMC4
proteasome 26S subunit, ATPase 4
total:8
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. 2010 to the paper
Cell Signaling Technology anti-phospho-Ser235/236-S6 antibody was used to perform immunocytochemistry in order to study the capacity of rapamycin to provide neuroprotection in Parkinson disease models. more
PSMC6
proteasome 26S subunit, ATPase 6
total:1
Physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing Rho guanine nucleotide exchange factors (RhoGEFs). 2005 to the paper
New England BioLabs antiphospho-p44/42 MAPK antibody and p44/42 MAPK antibody (PhosphoPlus p44/42 MAPK antibody kit) was used in western blot to study the physical and functional interactions of the lysophosphatidic acid receptors with PDZ domain-containing RhoGEFs.
PSMD1
proteasome 26S subunit, non-ATPase 1
PSMD11
proteasome 26S subunit, non-ATPase 11
PSMD12
proteasome 26S subunit, non-ATPase 12
PSMD13
proteasome 26S subunit, non-ATPase 13
PSMD14
proteasome 26S subunit, non-ATPase 14
PSMD2
proteasome 26S subunit, non-ATPase 2
total:1
HIV-1 replication through hHR23A-mediated interaction of Vpr with 26S proteasome. 2010 to the paper
Calbiochem rabbit polyclonal anti-19S proteasome S2 subunit antibody was used to perform western blot in order to clarify that hHR23A-mediated interaction of Vpr with proteasome plays an important role in viral replication.
PSMD4
proteasome 26S subunit, non-ATPase 4
total:3
HIV-1 replication through hHR23A-mediated interaction of Vpr with 26S proteasome. 2010 to the paper
Calbiochem rabbit polyclonal anti-19S proteasome S5a antibody was used to perform western blot in order to clarify that hHR23A-mediated interaction of Vpr with proteasome plays an important role in viral replication. more
PSMD5
proteasome 26S subunit, non-ATPase 5
PSMD7
proteasome 26S subunit, non-ATPase 7
PSMD8
proteasome 26S subunit, non-ATPase 8
PSMD9
proteasome 26S subunit, non-ATPase 9
total:13
ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. 2012 to the paper
Santa Cruz anti-p27 antibody was used to perform western blot in order to study the estrogen sensitivity and the acquisition of antiestrogen resistance in luminal breast cancer. more
PSME1
proteasome activator subunit 1
total:3
Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. 2010 to the paper
Affinity-Biomol International rabbit polyclonal anti-PA28alpha antibody was used for immunohistochemistry to determine the role of immunoproteasome in the Multiple Sclerosis. more
PSME2
proteasome activator subunit 2
total:1
Chronic ethanol feeding affects proteasome-interacting proteins. 2009 to the paper
BIOMOL anti-proteasome activator 28 subunit beta (PA28beta) antibodoy was used to perform western blot in order to confirm the effect on the expression of proteasome-interacting proteins caused by chronic ethanol feeding.
PSME3
proteasome activator subunit 3
PSMF1
proteasome inhibitor subunit 1
RPS27A
ribosomal protein S27a
total:5
Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD. 2009 to the paper
Santa Cruz Biotechnology anti-ubiquitin antibody was used in western blot in order to identify a novel complex of erasin-ubiquilin-p97/VCP and its function in ERAD. more
S3
proteasome 26S subunit, non-ATPase 3
SEC61A1
SEC61 translocon subunit alpha 1
SEC61A2
SEC61 translocon subunit alpha 2
SEC61B
SEC61 translocon subunit beta
total:1
Host ER-parasitophorous vacuole interaction provides a route of entry for antigen cross-presentation in Toxoplasma gondii-infected dendritic cells. 2009 to the paper
Proteintech Group anti-KDEL was used to perform immunofluorescence and immunogold labeling in order to demonstrate that pathogen-driven hER-PV interaction can faciliate Ag entry into the MHC class I pathway and CD8+ T cell.
SEC61G
SEC61 translocon subunit gamma
TAP1
transporter 1, ATP binding cassette subfamily B member
tapasin
TAP binding protein
UBC
ubiquitin C
total:7
The sphingolipid receptor S1PR2 is a receptor for Nogo-a repressing synaptic plasticity. 2014 to the paper
Enzo Life Sciences anti-Ubiquitin antibody was used to perform western blot in order to study synaptic plasticity. more
ubiquitin
ubiquitin B
total:34
BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. 2009 to the paper
Cell Signaling Technology mouse anti-ubiquitin monoclonal antibody was used in western blot in order to demonstrate that BCL6 interacts with HB-EGF-CTF and that this interaction might induce the cyclin D2 expression in human gastric cancer. more